Literature DB >> 25238097

Transforming growth factor β-mediated suppression of antitumor T cells requires FoxP1 transcription factor expression.

Tom L Stephen1, Melanie R Rutkowski1, Michael J Allegrezza1, Alfredo Perales-Puchalt1, Amelia J Tesone1, Nikolaos Svoronos1, Jenny M Nguyen1, Fahmida Sarmin1, Mark E Borowsky2, Julia Tchou3, Jose R Conejo-Garcia4.   

Abstract

Tumor-reactive T cells become unresponsive in advanced tumors. Here we have characterized a common mechanism of T cell unresponsiveness in cancer driven by the upregulation of the transcription factor Forkhead box protein P1 (Foxp1), which prevents CD8⁺ T cells from proliferating and upregulating Granzyme-B and interferon-γ in response to tumor antigens. Accordingly, Foxp1-deficient lymphocytes induced rejection of incurable tumors and promoted protection against tumor rechallenge. Mechanistically, Foxp1 interacted with the transcription factors Smad2 and Smad3 in preactivated CD8⁺ T cells in response to microenvironmental transforming growth factor-β (TGF-β), and was essential for its suppressive activity. Therefore, Smad2 and Smad3-mediated c-Myc repression requires Foxp1 expression in T cells. Furthermore, Foxp1 directly mediated TGF-β-induced c-Jun transcriptional repression, which abrogated T cell activity. Our results unveil a fundamental mechanism of T cell unresponsiveness different from anergy or exhaustion, driven by TGF-β signaling on tumor-associated lymphocytes undergoing Foxp1-dependent transcriptional regulation.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25238097      PMCID: PMC4174366          DOI: 10.1016/j.immuni.2014.08.012

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  44 in total

Review 1.  The three main stumbling blocks for anticancer T cells.

Authors:  Lukas Baitsch; Silvia A Fuertes-Marraco; Amandine Legat; Christiane Meyer; Daniel E Speiser
Journal:  Trends Immunol       Date:  2012-03-23       Impact factor: 16.687

Review 2.  CD8 T cell quiescence revisited.

Authors:  Sara E Hamilton; Stephen C Jameson
Journal:  Trends Immunol       Date:  2012-02-21       Impact factor: 16.687

3.  Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy.

Authors:  Matthew D Vesely; Robert D Schreiber
Journal:  Ann N Y Acad Sci       Date:  2013-05       Impact factor: 5.691

Review 4.  T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment.

Authors:  Joel Crespo; Haoyu Sun; Theodore H Welling; Zhigang Tian; Weiping Zou
Journal:  Curr Opin Immunol       Date:  2013-01-06       Impact factor: 7.486

5.  Network analysis reveals centrally connected genes and pathways involved in CD8+ T cell exhaustion versus memory.

Authors:  Travis A Doering; Alison Crawford; Jill M Angelosanto; Michael A Paley; Carly G Ziegler; E John Wherry
Journal:  Immunity       Date:  2012-11-15       Impact factor: 31.745

6.  High-avidity T cells are preferentially tolerized in the tumor microenvironment.

Authors:  Ziqiang Zhu; Vinod Singh; Stephanie K Watkins; Vincenzo Bronte; Jennifer L Shoe; Lionel Feigenbaum; Arthur A Hurwitz
Journal:  Cancer Res       Date:  2012-11-30       Impact factor: 12.701

7.  BATF-JUN is critical for IRF4-mediated transcription in T cells.

Authors:  Peng Li; Rosanne Spolski; Wei Liao; Lu Wang; Theresa L Murphy; Kenneth M Murphy; Warren J Leonard
Journal:  Nature       Date:  2012-09-19       Impact factor: 49.962

8.  Immunotherapy earns its spot in the ranks of cancer therapy.

Authors:  Drew Pardoll; Charles Drake
Journal:  J Exp Med       Date:  2012-02-13       Impact factor: 14.307

9.  Ovarian cancer progression is controlled by phenotypic changes in dendritic cells.

Authors:  Uciane K Scarlett; Melanie R Rutkowski; Adam M Rauwerdink; Jennifer Fields; Ximena Escovar-Fadul; Jason Baird; Juan R Cubillos-Ruiz; Ana C Jacobs; Jorge L Gonzalez; John Weaver; Steven Fiering; Jose R Conejo-Garcia
Journal:  J Exp Med       Date:  2012-02-20       Impact factor: 14.307

10.  Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo.

Authors:  Yan Zheng; Yuanyuan Zha; Gregory Driessens; Frederick Locke; Thomas F Gajewski
Journal:  J Exp Med       Date:  2012-11-05       Impact factor: 14.307

View more
  57 in total

1.  Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target.

Authors:  Alfredo Perales-Puchalt; Nikolaos Svoronos; Melanie R Rutkowski; Michael J Allegrezza; Amelia J Tesone; Kyle K Payne; Jayamanna Wickramasinghe; Jenny M Nguyen; Shane W O'Brien; Kiranmai Gumireddy; Qihong Huang; Mark G Cadungog; Denise C Connolly; Julia Tchou; Tyler J Curiel; Jose R Conejo-Garcia
Journal:  Clin Cancer Res       Date:  2016-07-19       Impact factor: 12.531

2.  Enhancing Adoptive Cell Therapy of Cancer through Targeted Delivery of Small-Molecule Immunomodulators to Internalizing or Noninternalizing Receptors.

Authors:  Yiran Zheng; Li Tang; Llian Mabardi; Sudha Kumari; Darrell J Irvine
Journal:  ACS Nano       Date:  2017-03-01       Impact factor: 15.881

3.  TGF-β inhibits IL-7-induced proliferation in memory but not naive human CD4+ T cells.

Authors:  Thao P Nguyen; Scott F Sieg
Journal:  J Leukoc Biol       Date:  2017-06-06       Impact factor: 4.962

Review 4.  Transforming growth factor beta1 and aldosterone.

Authors:  Kota Matsuki; Catherine K Hathaway; Albert S Chang; Oliver Smithies; Masao Kakoki
Journal:  Curr Opin Nephrol Hypertens       Date:  2015-03       Impact factor: 2.894

5.  Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model.

Authors:  Katherine A Waugh; Sonia M Leach; Brandon L Moore; Tullia C Bruno; Jonathan D Buhrman; Jill E Slansky
Journal:  J Immunol       Date:  2016-07-01       Impact factor: 5.422

6.  SATB1 Expression Governs Epigenetic Repression of PD-1 in Tumor-Reactive T Cells.

Authors:  Tom L Stephen; Kyle K Payne; Ricardo A Chaurio; Michael J Allegrezza; Hengrui Zhu; Jairo Perez-Sanz; Alfredo Perales-Puchalt; Jenny M Nguyen; Ana E Vara-Ailor; Evgeniy B Eruslanov; Mark E Borowsky; Rugang Zhang; Terri M Laufer; Jose R Conejo-Garcia
Journal:  Immunity       Date:  2017-01-17       Impact factor: 31.745

7.  Tumor Cell-Independent Estrogen Signaling Drives Disease Progression through Mobilization of Myeloid-Derived Suppressor Cells.

Authors:  Nikolaos Svoronos; Alfredo Perales-Puchalt; Michael J Allegrezza; Melanie R Rutkowski; Kyle K Payne; Amelia J Tesone; Jenny M Nguyen; Tyler J Curiel; Mark G Cadungog; Sunil Singhal; Evgeniy B Eruslanov; Paul Zhang; Julia Tchou; Rugang Zhang; Jose R Conejo-Garcia
Journal:  Cancer Discov       Date:  2016-09-30       Impact factor: 39.397

Review 8.  Regulatory circuits of T cell function in cancer.

Authors:  Daniel E Speiser; Ping-Chih Ho; Grégory Verdeil
Journal:  Nat Rev Immunol       Date:  2016-08-16       Impact factor: 53.106

9.  Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies.

Authors:  Arta M Monjazeb; Michael S Kent; Steven K Grossenbacher; Christine Mall; Anthony E Zamora; Annie Mirsoian; Mingyi Chen; Amir Kol; Stephen L Shiao; Abhinav Reddy; Julian R Perks; William T N Culp; Ellen E Sparger; Robert J Canter; Gail D Sckisel; William J Murphy
Journal:  Clin Cancer Res       Date:  2016-03-15       Impact factor: 12.531

10.  Cyclooxygenase-2 expressed hepatocellular carcinoma induces cytotoxic T lymphocytes exhaustion through M2 macrophage polarization.

Authors:  Xiaodong Xun; Changkun Zhang; Siqi Wang; Shihua Hu; Xiao Xiang; Qian Cheng; Zhao Li; Yang Wang; Jiye Zhu
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.